Breast Cancer Attributable Costs in Germany: A Top-Down Approach Based on Sickness Funds Data

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Gruber, Emil Victor ^a   Stock, Stephanie ^b   Stollenwerk, Björn ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE SPECIFIC CARE; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; FUNDING; GERMANY; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY;

BREAST NEOPLASMS; COST OF ILLNESS; FEMALE; GERMANY; HUMANS;

EID: 84870865668     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051312     Document Type: Article

References (34)

1. Boyle P, Ferlay J, (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481-488.
2. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
3. Katalinic A, Pritzkuleit R, Waldmann A, (2009) Recent trends in breast cancer incidence and mortality in Germany. Breast Care (Basel) 4: 75-80.
4. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, et al. (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592.
5. Parkin DM, Bray F, Ferlay J, Pisani P, (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156.
6. Max W, Sung HY, Stark B, (2009) The economic burden of breast cancer in California. Breast Cancer Res Treat 116: 201-207.
7. Pisani P (2009) Breast cancer - Interventions. Bilthoven: EUPHIX, EUphact.
8. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL, (1995) Efficacy of screening mammography. A meta-analysis. JAMA 273: 149-154.
9. Grunfeld E, Gray A, Mant D, Yudkin P, Adewuyi-Dalton R, et al. (1999) Follow-up of breast cancer in primary care vs specialist care: results of an economic evaluation. Br J Cancer 79: 1227-1233.
10. Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, et al. (1993) Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 341: 973-978.
11. Rajan R, Gafni A, Levine M, Hirsh J, Gent M, (1995) Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation. J Clin Oncol 13: 42-46.
12. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, et al. (1993) Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11: 2101-2111.
13. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford University Press.
14. Shenoy AU, Aljutaili M, Stollenwerk B (2012) Limited economic evidence of carotid artery stenosis diagnosis and treatment: a systematic review. Eur J Vasc Endovasc Surg. Doi: 10.1016/j.ejvs.2012.08.010. [Epub ahead of print].
15. Braun S, Mittendorf T, Menschik T, Greiner W, von der Schulenburg JM, (2009) Cost effectiveness of exemestane versus tamoxifen in post-menopausal women with early breast cancer in Germany. Breast Care (Basel) 4: 389-396.
16. Lux MP, Hartmann M, Jackisch C, Raab G, Schneeweiss A, et al. (2009) Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model. Breast Cancer Res Treat 117: 305-317.
17. Paterson A, McCloskey E, Redzepovic J, Ott I, Gust R, (2008) Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients. J Int Med Res 36: 400-413.
18. Lauterbach KW, Wille E, Lüngen M, Stock S, Wendland G, et al. (2001) Modell eines fairen Wettbewerbs durch den Risikostrukturausgleich. Köln, Mannheim: Institut für Gesundheitsökonomie und klinische Epidemiologie (IGKE) der Universität zu Köln und Lehrstuhl für Volkswirtschaftslehre der Universität Mannheim.
19. Stock S, Redaelli M, Luengen M, Wendland G, Civello D, et al. (2005) Asthma: prevalence and cost of illness. Eur Respir J 25: 47-53.
20. Stock SA, Stollenwerk B, Redaelli M, Civello D, Lauterbach KW, (2008) Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insurance. J Womens Health (Larchmt) 17: 343-354.
21. Stollenwerk B, Stock S, Siebert U, Lauterbach KW, Holle R, (2010) Uncertainty assessment of input parameters for economic evaluation: Gauss's error propagation, an alternative to established methods. Med Decis Making 30: 304-313.
22. Wood SN (2006) Generalized Additive Models: an Introduction with R. London: Chapman & Hall/CRC.
23. Calvo A, (2001) Breast cancer in Germany: a health education perspective. Int Electron J Health Educ 4: 19-22.
24. R Development Core Team (2010) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
25. Wood SN (2010) mgcv: GAMs with GCV/AIC/REML smoothness estimation and GAMMs by PQL. 1.6-2 ed: r-project.org.
26. Stock SA, Redaelli M, Wendland G, Civello D, Lauterbach KW, (2006) Diabetes - prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany. Diabet Med 23: 299-305.
27. Broekx S, Den Hond E, Torfs R, Remacle A, Mertens R, et al. (2011) The costs of breast cancer prior to and following diagnosis. Eur J Health Econ 12: 311-317.
28. Khanna R, Madhavan SS, Bhanegaonkar A, Remick SC, (2011) Prevalence, healthcare utilization, and costs of breast cancer in a state Medicaid fee-for-service program. J Womens Health (Larchmt) 20: 739-747.
29. Baser O, Wei W, Henk HJ, Teitelbaum A, Xie L, (2012) Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry. Curr Med Res Opin 28: 1-10.
30. Ihbe-Heffinger A, Paessens BJ, von Schilling C, Shlaen M, Gottschalk N, et al. (2011) Management of febrile neutropenia - a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer. Onkologie 34: 241-246.
31. Barron JJ, Quimbo R, Nikam PT, Amonkar MM, (2008) Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat 109: 367-377.
32. Larg A, Moss JR, (2011) Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics 29: 653-671.
33. Zindel S, Stock S, Muller D, Stollenwerk B, (2012) A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting. BMC Health Serv Res 12: 192.
34. Wilking N, Jonsson B (2005) A pan-European Comparison regarding Patient Access to Cancer Drugs. Stockholm, Sweden: Karolinska Institutet with Stockholm School of Economics.